{"id":13363,"date":"2025-09-28T16:06:22","date_gmt":"2025-09-28T14:06:22","guid":{"rendered":"https:\/\/www.kliinikum.ee\/yhendlabor\/?page_id=13363"},"modified":"2025-12-09T22:50:14","modified_gmt":"2025-12-09T20:50:14","slug":"lipoproteiin-a-sp-lpa","status":"publish","type":"page","link":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/lipoproteiin-a-sp-lpa\/","title":{"rendered":"Lipoproteiin a (S,P-Lp(a))"},"content":{"rendered":"\n

Kliinilise keemia ja laboratoorse hematoloogia osakond<\/em><\/p>\n\n\n\n

Lipoproteiin a<\/strong> on v\u00e4ikese tihedusega lipoproteiinile (LDL) sarnanev osake, koosnedes apolipoproteiin B100 molekulist, mille k\u00fclge on disulfiidsillaga kovalentselt \u00fchendatud apolipoproteiin a molekul. Lipoproteiin a on v\u00e4ga aterogeense toimega. Kuna tema koostises sisalduv apolipoproteiin a on homoloogne plasminogeeniga omab Lp(a) ka antifibrinol\u00fc\u00fctilist toimet, samuti trombogeneesi soodustavat toimet stimuleerides PAI-1 (plasminogeeni aktivaatori \u00a0inhibiitor 1) sekretsiooni. Lipoproteiin a s\u00fcnteesitakse maksas ja metaboliseeritakse neerude kaudu. Lp(a) tase on geneetiliselt determineeritud, seda ei m\u00f5juta vanus ega dieet ning v\u00e4\u00e4rtus seerumis on elu jooksul suhteliselt stabiilne, varieerudes siiski s\u00f5ltuvalt etnilisest grupist (nt afroameeriklastel on tavaliselt tase k\u00f5rgem kui valgel rassil).<\/p>\n\n\n\n

Uuritav materjal, selle v\u00f5tmine, saatmine ja s\u00e4ilitamine<\/strong><\/p>\n\n\n\n

<\/td>Katsuti<\/strong><\/td>Geeli ja h\u00fc\u00fcbimisaktivaatoriga katsuti (punane kollase r\u00f5ngaga v\u00f5i kollane kork) v\u00f5i geeliga LH-katsuti (roheline kollase r\u00f5ngaga v\u00f5i heleroheline kork)<\/td><\/tr>
<\/td>S\u00e4ilivus<\/strong><\/td>Seerum\/plasma toatemperatuuril kaheksa tundi, +4\u00b0C kaks p\u00e4eva, -70\u00b0C pikemaajaliselt<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Anal\u00fc\u00fcsi tegemise aeg:<\/strong> t\u00f6\u00f6p\u00e4eviti<\/p>\n\n\n\n

Anal\u00fc\u00fcsimeetod:<\/strong> immuunturbidimeetriline meetod<\/p>\n\n\n\n

Referentsv\u00e4\u00e4rtused<\/strong><\/p>\n\n\n\n

Kardiovaskulaarset riski suurendab Lp(a) v\u00e4\u00e4rtus \u2265 105 nmol\/L (allikas Euroopa Kardioloogide Seltsi ja Euroopa Ateroskleroosi \u00dchingu (EAS) d\u00fcslipideemiate juhis (2019) ning Euroopa Ateroskleroosi \u00dchingu (EAS) ja Euroopa Laborimeditsiini F\u00f6deratsiooni (EFLM) juhis (2019).<\/p>\n\n\n\n

N\u00e4idustus ja kliiniline t\u00e4hendus<\/strong><\/p>\n\n\n\n

Lipoproteiin a on iseseisev s\u00fcdame- ja veresoonkonna haiguste riskifaktor. V\u00e4ga k\u00f5rge Lp(a) taseme (> 430 nmol\/L) puhul on elupuhune kardiaalne risk suurenenud sarnaselt perekondlikule h\u00fcperkolesteroleemiale.<\/p>\n\n\n\n

Lp(a) k\u00f5rgenenud sisaldust veres ei langeta statiinravi, kuid see on m\u00f5jutatav nt PCSK9 inhibiitorite jt uuemate lipiide langetavate ravimitega.<\/p>\n\n\n\n

K\u00f5igil aterosklerootilise kardiovaskulaarse haiguse riskiga patsientidel tuleks v\u00e4hemalt \u00fchekordselt m\u00e4\u00e4rata lipoproteiin a hulk. Eriti oluline on see lipiidelangetava ravi halva toimimise korral.<\/p>\n\n\n\n

Lp(a) tavap\u00e4rasest k\u00f5rgem tase v\u00f5ib esineda raseduse, kroonilise neeruhaiguse ja h\u00fcpot\u00fcreoosi korral ning madalamat taset v\u00f5ib esineda kroonilise maksahaiguse korral.<\/p>\n\n\n\n

Koostajad: Signe Feodorov, Katrin Reimand
Koostatud 06.09.2022<\/p>\n","protected":false},"excerpt":{"rendered":"

Kliinilise keemia ja laboratoorse hematoloogia osakond Lipoproteiin a on v\u00e4ikese tihedusega lipoproteiinile (LDL) sarnanev osake, koosnedes apolipoproteiin B100 molekulist, mille k\u00fclge on disulfiidsillaga kovalentselt \u00fchendatud apolipoproteiin a molekul. Lipoproteiin a on v\u00e4ga aterogeense toimega. Kuna tema koostises sisalduv apolipoproteiin a on homoloogne plasminogeeniga omab Lp(a) ka antifibrinol\u00fc\u00fctilist toimet, samuti trombogeneesi soodustavat toimet stimuleerides PAI-1 (plasminogeeni […]<\/p>\n","protected":false},"author":38,"featured_media":0,"parent":7286,"menu_order":31,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","footnotes":""},"class_list":["post-13363","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nLipoproteiin a (S,P-Lp(a)) - \u00dchendlabor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/lipoproteiin-a-sp-lpa\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lipoproteiin a (S,P-Lp(a)) - \u00dchendlabor\" \/>\n<meta property=\"og:description\" content=\"Kliinilise keemia ja laboratoorse hematoloogia osakond Lipoproteiin a on v\u00e4ikese tihedusega lipoproteiinile (LDL) sarnanev osake, koosnedes apolipoproteiin B100 molekulist, mille k\u00fclge on disulfiidsillaga kovalentselt \u00fchendatud apolipoproteiin a molekul. Lipoproteiin a on v\u00e4ga aterogeense toimega. Kuna tema koostises sisalduv apolipoproteiin a on homoloogne plasminogeeniga omab Lp(a) ka antifibrinol\u00fc\u00fctilist toimet, samuti trombogeneesi soodustavat toimet stimuleerides PAI-1 (plasminogeeni […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/lipoproteiin-a-sp-lpa\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00dchendlabor\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-09T20:50:14+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutit\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/kliinilise-keemia-uuringud\\\/lipoproteiin-a-sp-lpa\\\/\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/kliinilise-keemia-uuringud\\\/lipoproteiin-a-sp-lpa\\\/\",\"name\":\"Lipoproteiin a (S,P-Lp(a)) - \u00dchendlabor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\"},\"datePublished\":\"2025-09-28T14:06:22+00:00\",\"dateModified\":\"2025-12-09T20:50:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/kliinilise-keemia-uuringud\\\/lipoproteiin-a-sp-lpa\\\/#breadcrumb\"},\"inLanguage\":\"et\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/kliinilise-keemia-uuringud\\\/lipoproteiin-a-sp-lpa\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/kliinilise-keemia-uuringud\\\/lipoproteiin-a-sp-lpa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"K\u00e4siraamat\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Kliinilise keemia uuringud\",\"item\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/kasiraamat\\\/kliinilise-keemia-uuringud\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Lipoproteiin a (S,P-Lp(a))\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/#website\",\"url\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/\",\"name\":\"\u00dchendlabor\",\"description\":\"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.kliinikum.ee\\\/yhendlabor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"et\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lipoproteiin a (S,P-Lp(a)) - \u00dchendlabor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/lipoproteiin-a-sp-lpa\/","og_locale":"et_EE","og_type":"article","og_title":"Lipoproteiin a (S,P-Lp(a)) - \u00dchendlabor","og_description":"Kliinilise keemia ja laboratoorse hematoloogia osakond Lipoproteiin a on v\u00e4ikese tihedusega lipoproteiinile (LDL) sarnanev osake, koosnedes apolipoproteiin B100 molekulist, mille k\u00fclge on disulfiidsillaga kovalentselt \u00fchendatud apolipoproteiin a molekul. Lipoproteiin a on v\u00e4ga aterogeense toimega. Kuna tema koostises sisalduv apolipoproteiin a on homoloogne plasminogeeniga omab Lp(a) ka antifibrinol\u00fc\u00fctilist toimet, samuti trombogeneesi soodustavat toimet stimuleerides PAI-1 (plasminogeeni […]","og_url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/lipoproteiin-a-sp-lpa\/","og_site_name":"\u00dchendlabor","article_modified_time":"2025-12-09T20:50:14+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutit"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/lipoproteiin-a-sp-lpa\/","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/lipoproteiin-a-sp-lpa\/","name":"Lipoproteiin a (S,P-Lp(a)) - \u00dchendlabor","isPartOf":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website"},"datePublished":"2025-09-28T14:06:22+00:00","dateModified":"2025-12-09T20:50:14+00:00","breadcrumb":{"@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/lipoproteiin-a-sp-lpa\/#breadcrumb"},"inLanguage":"et","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/lipoproteiin-a-sp-lpa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/lipoproteiin-a-sp-lpa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/"},{"@type":"ListItem","position":2,"name":"K\u00e4siraamat","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/"},{"@type":"ListItem","position":3,"name":"Kliinilise keemia uuringud","item":"https:\/\/www.kliinikum.ee\/yhendlabor\/kasiraamat\/kliinilise-keemia-uuringud\/"},{"@type":"ListItem","position":4,"name":"Lipoproteiin a (S,P-Lp(a))"}]},{"@type":"WebSite","@id":"https:\/\/www.kliinikum.ee\/yhendlabor\/#website","url":"https:\/\/www.kliinikum.ee\/yhendlabor\/","name":"\u00dchendlabor","description":"Hoolivus, Uuendusmeelsus, P\u00e4devus ja Usaldusv\u00e4\u00e4rsus","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kliinikum.ee\/yhendlabor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"et"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"Kadi Siigur","author_link":"https:\/\/www.kliinikum.ee\/yhendlabor\/author\/kadisi\/"},"uagb_comment_info":0,"uagb_excerpt":"Kliinilise keemia ja laboratoorse hematoloogia osakond Lipoproteiin a on v\u00e4ikese tihedusega lipoproteiinile (LDL) sarnanev osake, koosnedes apolipoproteiin B100 molekulist, mille k\u00fclge on disulfiidsillaga kovalentselt \u00fchendatud apolipoproteiin a molekul. Lipoproteiin a on v\u00e4ga aterogeense toimega. Kuna tema koostises sisalduv apolipoproteiin a on homoloogne plasminogeeniga omab Lp(a) ka antifibrinol\u00fc\u00fctilist toimet, samuti trombogeneesi soodustavat toimet stimuleerides PAI-1 (plasminogeeni…","_links":{"self":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/13363","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/comments?post=13363"}],"version-history":[{"count":0,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/13363\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/pages\/7286"}],"wp:attachment":[{"href":"https:\/\/www.kliinikum.ee\/yhendlabor\/wp-json\/wp\/v2\/media?parent=13363"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}